

## Original Article

# Hydrogen peroxide and cisplatin regulate the ROS/PKM2 pathway to affect the growth of cancer

Li-Yuan Bai<sup>1,2</sup>, Chang-Fang Chiu<sup>1,3</sup>, Chia-Yung Wu<sup>1</sup>, Jing-Ru Weng<sup>4,5,6</sup>

<sup>1</sup>Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan; <sup>2</sup>College of Medicine, China Medical University, Taichung 404, Taiwan; <sup>3</sup>Cancer Center, China Medical University Hospital, Taichung 404, Taiwan; <sup>4</sup>Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan; <sup>5</sup>Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan; <sup>6</sup>Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan

Received February 3, 2025; Accepted September 10, 2025; Epub September 25, 2025; Published September 30, 2025

**Abstract:** Aberrant production of reactive oxygen species (ROS) cause DNA damage which led to the chronic diseases and cancer. During glycolysis, the enzyme pyruvate kinase M2 (PKM2) is responsible for energy metabolism and its overexpression can be found in various malignancies. To investigate the impact of PKM2 and ROS, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and cisplatin were used. This study showed that H<sub>2</sub>O<sub>2</sub> and cisplatin induced ROS production and apoptosis in these four tumor cells: pancreatic cancer, oral cancer, gastric cancer, and hepatocellular carcinoma. In addition, H<sub>2</sub>O<sub>2</sub>- and cisplatin-increased apoptosis was partially reduced by pre-treatment with an antioxidant N-acetylcysteine (NAC) in SC-M1 gastric cancer and HSC-3 oral cancer cells. Interestingly, the levels of p-PKM2 in the nucleus were downregulated after treatment with H<sub>2</sub>O<sub>2</sub> and cisplatin. This phenomenon was reversed with the combination of NAC. These findings provide PKM2 may be a potential target for anticancer therapy.

**Keywords:** Apoptosis, cisplatin, hydrogen peroxide, PKM2, reactive oxygen species

## Introduction

According to the statistically estimation from the American Cancer Society, the cancer-related deaths are more than 0.6 million in America in 2024 [1]. Current cancer treatments include surgery, chemotherapy, molecular-targeted therapy, and radiotherapy. However, there are some limitations that compromise the efficacy of conventional antitumor therapy [2]. In advanced gastric cancer, for example, combination chemotherapy (cisplatin, bevacizumab, fluorouracil, and capecitabine) applied for the efficacy results in the median overall survival is 12.1-13.1 months [3]. Cao et al. reported that the high re-occurrence of oral squamous cell carcinoma was related to non-specific cell death after chemotherapy treatment [4]. In addition, chemoresistance is another critical obstacle that may affect the treatment of solid tumors. New strategies or approaches are urgently needed for the therapy of cancer.

Aberrant reactive oxygen species (ROS) is part of the oxidative stress, which promotes the progression of inflammatory diseases and the pathogenesis of cancer, aging, and diabetes mellitus [5]. Free radicals, including hydroxyl radicals, superoxide anions, peroxy radicals, and non-radical molecules like hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), are secondary messengers involved in the initiation of free radical chains causing extreme damage to the cells [6]. Several studies showed that ROS were oncogenic, promoted tumorigenesis, angiogenesis, and metastasis [6, 7]. Increased levels of angiotensin-converting enzyme 1 by H<sub>2</sub>O<sub>2</sub> causes trophoblast cell damage *in vitro* [8]. A previous study revealed that H<sub>2</sub>O<sub>2</sub> is released from metal peroxides, alleviates tumor hypoxia in the tumor microenvironment [9]. However, it is worth nothing that ROS represents a double-edged way in tumor cells. Imbalance production of ROS could initiate oxidative stress-induced tumor cell death [10]. Certain anti-tumor agents, including molecular-

targeted drugs and chemotherapeutic agents, inhibit tumor growth by increasing ROS production [11]. For example, the gemcitabine prodrug was activated in the presence of H<sub>2</sub>O<sub>2</sub>, leading to apoptosis in pancreatic cancer cells [12]. The combination therapy of cisplatin and pitavastatin, a HMG-CoA inhibitor suppressed the growth of cervical cancer through increasing ROS production and DNA damage [13]. In addition to DNA damage, ROS alters several signaling pathways, including NF- $\kappa$ B [14], MAPK kinase [15], PI3K/Akt, NRF2 [16], and mitochondrial oxidative metabolism [17].

Pyruvate kinase M2 (PKM2) is an enzyme involved in the final step of glycolysis, catalyzing the conversion of phosphoenolpyruvate to pyruvate with the concomitant production of ATP, and it plays a central role in the Warburg effect [18]. PKM2 may either be a dimer or a tetramer, depending on its physiological conditions [18]. Numerous studies have reported that PKM2 contributes to tumor growth and cell proliferation by supplying the anabolic conditions required [19, 20]. Over-expression of PKM2 is involved in the progression of numerous cancers, including pancreatic cancer, oral cancer, and hepatocellular carcinoma (HCC) [19, 20]. In addition, PKM2 activation was responsible for the resistance of the chemotherapeutic drugs [21]. A previous report showed that the transcription factors including p53, HIF-1 $\alpha$ , and c-Myc modulated the activity/ expression of PKM2 through Warburg effect which are critical for the metabolism of tumor cells [22]. Therefore, multiple evidences revealed that PKM2 can serve as a potential target for cancer therapy [23-25]. For example, the combination of PKM2 knockdown and estrogen enhanced apoptosis in colon cancer cells [26]. Polyphyllin II, a saponin, induces apoptosis by decreasing nuclear PKM2 and its downstream genes such *Glut1* and *MYC* in fibrosarcoma [27]. Wang et al. reported that shikonin, a PKM2 inhibitor used in treatment of bladder cancer, enhanced the sensitivity to cisplatin by inducing necroptosis [24]. Notably, PKM2 knockdown decreased the intracellular ROS generation, inhibited cell migration and invasion of tongue tumor *in vitro* and *in vivo* [28]. A recent study reported that lambertianic acid, a diterpene derivative, suppresses prostate cancer cell growth through modulation of ROS/PKM2/STAT3 signaling [29], highlighting

the contribution of ROS signaling to PKM2 regulation in tumor progression [28, 29]. Cisplatin, a well-known chemotherapeutic agent, has been found the anti-tumor effects through the interaction between PKM2 and mTOR in cervical cancer [30]. However, the role of PKM2 or the correlation with Warburg effect in H<sub>2</sub>O<sub>2</sub>- and cisplatin- treated cancers, including gastric cancer, oral cancer, and HCC, remains ambiguous. This study, we evaluated the effects of H<sub>2</sub>O<sub>2</sub> and cisplatin against tumor cells and showed that the apoptotic mechanism of H<sub>2</sub>O<sub>2</sub> and cisplatin were associated with ROS/PKM2/STAT3 signaling related to the Warburg effect.

### Materials and methods

#### *Cell lines and chemical reagents*


SC-M1 gastric adenocarcinoma cell line was obtained from ATCC. Hep3B hepatocellular carcinoma cells and PANC-1 pancreatic ductal adenocarcinoma cells were gifts from Professor Po-Chen Chu. The above cells were maintained in DMEM (Invitrogen) medium. The HSC-3 oral cancer cells were purchased from JCRB cell Bank and cultured in DMEM/F12 medium. All of the cell lines were cultured in the environment containing 10% fetal bovine serum at 37°C. Antibodies used were as follows: p-PKM2 (Tyr105), PKM2, fibrillarin, LC3B, p-STAT3 (Tyr705), STAT3, and GADPH (Cell Signaling Technology).

#### *Determination of cell viability*

SC-M1, HSC-3, PANC-1, and Hep3B cells were plated in 96-well plates at a density of  $5 \times 10^3$  per well for 24 h. Then, these cell lines were treated with DMSO or H<sub>2</sub>O<sub>2</sub> (10, 25, 50, 75, and 100  $\mu$ M) or cisplatin (5, 10, 20, 50, 75, and 100  $\mu$ M). After 24-h treatment, 100  $\mu$ L MTT reagent was added and maintained for 4 h, followed by detection of the optical density at 450 nm using a microplate reader. The percentage of cell survival was assessed using MTT colorimetric assay.

#### *Flow cytometry analysis for apoptosis and ROS determination*

SC-M1, HSC-3, PANC-1, and Hep3B cells were seeded in 6-well plates at  $2 \times 10^5$ /well. For apoptosis determination, after treatment with DMSO or drug for 24 h, the reagent of annexin



**Figure 1.** Anti-proliferative effects of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (A) and cisplatin (B) in four cell lines: SC-M1 gastric cancer, HSC-3 oral cancer, PANC-1 pancreatic cancer, and Hep3B hepatocellular carcinoma. Cells were treated with H<sub>2</sub>O<sub>2</sub> or cisplatin for 24 h. Cell viability was determined using MTT assays. Points, means; bars, S.D. (*n* = 3). \**P* < 0.05, \*\**P* < 0.01.

V-FITC/PI (5 μl) were added for 20 min at room temperature. Then, the percentage of the apoptotic cells were measured by a flow cytometer (BD FACS Aria, Franklin Lakes, NJ). To detect ROS generation, DMSO- or cisplatin- or H<sub>2</sub>O<sub>2</sub>-treated cells were collected and washed with PBS. Then, these cells were stained with the probe (DCFH-DA, 5 μM) in the dark condition. The fluorescence intensity of cells was detected by a flow cytometer.

#### Preparation of nuclear and cytosolic extract

SC-M1 and HSC-3 cell lines (1 × 10<sup>6</sup>) were treated with DMSO or H<sub>2</sub>O<sub>2</sub> or cisplatin. After 24 h, nuclear and cytosolic extracts were collected using Nuclear Protein Extraction Kit (Thermo Fisher Scientific, Maltham, MA).

#### Western blotting

The protein samples (5 μg) were separated by SDS-PAGE gel and transferred to nitrocellulose membranes. Nonspecific binding of the antibody was blocked with milk containing PBST for 40 min, and the membranes were maintained with primary antibodies overnight. Then, the appropriate secondary antibodies were added into the containers of these membranes for at least 1 h with shaking. The signals detected using an ECL kit (Amersham).

#### Statistical analysis

All experiments in the present study were conducted for three times (*n* = 3). The statistically analysis for these data were processed using Student's *t* tests. *P* values < 0.05 means significant.

#### Results

##### *H<sub>2</sub>O<sub>2</sub> and cisplatin inhibit growth of tumor cells*

We first explored the viability of H<sub>2</sub>O<sub>2</sub> and cisplatin against these four strains of tumor cells including gastric cancer (SC-M1), oral cancer (HSC-3), pancreatic cancer (PANC-1), and HCC (Hep3B) using the MTT assays. After the treatment of H<sub>2</sub>O<sub>2</sub> (10, 25, 50, 75, and 100 μM) for 24 h, the results reveal that SC-M1 cells exhibited the highest sensitivity to H<sub>2</sub>O<sub>2</sub> (Figure 1A). The IC<sub>50</sub> values of H<sub>2</sub>O<sub>2</sub> are between 30.2 μM and 60.3 μM for the four cancer cell lines evaluated (Table 1). Similar to the findings of H<sub>2</sub>O<sub>2</sub> in

**Table 1.** Cytotoxicity of H<sub>2</sub>O<sub>2</sub> and cisplatin in four tumor cell lines

| Compound                                   | IC <sub>50</sub> (μM) |                    |                     |                    |
|--------------------------------------------|-----------------------|--------------------|---------------------|--------------------|
|                                            | SC-M1 <sup>b</sup>    | HSC-3 <sup>b</sup> | PANC-1 <sup>b</sup> | Hep3B <sup>b</sup> |
| H <sub>2</sub> O <sub>2</sub> <sup>a</sup> | 30.2 ± 1.0            | 31.6 ± 3.7         | 60.3 ± 6.1          | 48.5 ± 1.0         |
| Cisplatin                                  | 9.7 ± 1.6             | 27.0 ± 5.4         | 94.7 ± 15.8         | 49.3 ± 19.5        |

<sup>a</sup>Data are presented as mean ± S.E.M. (n = 3). <sup>b</sup>Key to all cell lines: SC-M1, human stomach adenocarcinoma; HSC-3, human oral squamous cell carcinoma; PANC-1, human pancreatic adenocarcinoma; Hep3B, human hepatocellular carcinoma.


9.7 μM, but also inhibited the cell proliferation of the other cancer cell lines (**Figure 1B**; **Table 1**).

*H<sub>2</sub>O<sub>2</sub> and cisplatin increase ROS production*

Multiple evidences have been shown that the imbalance of ROS production is related with tumor progression and carcinogenesis [10, 11]. In this study, the ROS generation after the treatment of H<sub>2</sub>O<sub>2</sub> or cisplatin were also examined. The results revealed that the ROS production were increased in H<sub>2</sub>O<sub>2</sub>-treated cells (**Figure 2A**). *N*-acetylcysteine (NAC), a ROS scavenger, was used for the further investigation of the role of ROS. The combination of NAC diminished the production of ROS induced by H<sub>2</sub>O<sub>2</sub> (**Figure 2A**). Meanwhile, cisplatin also increased the ROS generation (**Figure 2B**). Compared to that of cisplatin alone, the combination of NAC partly reversed the cisplatin-induced increase in ROS production in SC-M1 and HSC-3 cells (**Figure 2B**).

*The ROS scavenger rescues H<sub>2</sub>O<sub>2</sub>- and cisplatin-mediated cytotoxicity*


The SC-M1, HSC-3, PANC-1, and Hep3B cell lines were pre-treated with 5 mM NAC in the presence of either H<sub>2</sub>O<sub>2</sub> or cisplatin, to determine if ROS production contributed to H<sub>2</sub>O<sub>2</sub>- or cisplatin-mediated cytotoxicity. As shown in **Figure 3A**, the percentage viability increased with the combination of NAC and H<sub>2</sub>O<sub>2</sub> compared with that of H<sub>2</sub>O<sub>2</sub> alone. A similar phenomenon was observed with cisplatin treatment (**Figure 3B**).



**Figure 2.** Analysis of reactive oxygen species in hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (A) and cisplatin (B) in SC-M1 gastric cancer, HSC-3 oral cancer, PANC-1 pancreatic cancer, and Hep3B hepatocellular carcinoma cell lines. Cells were treated with H<sub>2</sub>O<sub>2</sub> or cisplatin, either alone or in combination with *N*-acetylcysteine (NAC) and stained with carboxy-DCFDA. Data is presented as the mean ± S.D. (n = 3). \**P* < 0.05, \*\**P* < 0.01, as compared with the control group. #*P* < 0.05, ##*P* < 0.01, compared with H<sub>2</sub>O<sub>2</sub>- and cisplatin-treated group at the same concentration. NS, statistically not significant.

SC-M1 cells, cisplatin not only showed the extremely susceptibility with an IC<sub>50</sub> value of

phenomenon was observed with cisplatin treatment (**Figure 3B**).



**Figure 3.** Hydrogen peroxide ( $H_2O_2$ )- (A) and cisplatin-mediated (B) cytotoxicity on reactive oxygen species generation in SC-M1 gastric cancer, HSC-3 oral cancer, PANC-1 pancreatic cancer, and Hep3B hepatocellular carcinoma cell lines. Cells were pre-treated with 5 mM NAC for 15 min, then incubated with  $H_2O_2$  or cisplatin for 24 h. Cell viability was determined using the MTT assay. Points, means; bars, S.D. ( $n = 3$ ). \* $P < 0.05$ , \*\* $P < 0.01$ .

#### ROS production is involved in $H_2O_2$ - and cisplatin-induced apoptosis

To determine the impact of ROS on apoptosis, these drug-treated cancer cell lines were used and analyzed using flow cytometry. The results showed that  $H_2O_2$  induce apoptosis in three cancer cell lines including SC-M1, HSC-3, and PANC-1, except for Hep3B cells (Figure 4A). In Hep3B cells (Figure 4A), there is no apoptotic


cells were significantly changed after treatment of  $H_2O_2$  at 100  $\mu M$  (the highest concentrations). We further investigate whether the other cell death pathway is involved after treatment of  $H_2O_2$  in Hep3B cells. As shown in Figure S1A,  $H_2O_2$  increased the levels of LC3B-II, an autophagy biomarker, in a concentration-dependent manner in Hep3B cells. In the presence of an autophagic inhibitor chloroquine (CQ) partially reversed  $H_2O_2$ -induced cytotoxicity which suggested that  $H_2O_2$  induces autophagy (Figure S1B). In the combination of NAC, the percentage of apoptosis were decreased in  $H_2O_2$ -treated cells (Figure 4A). Unlike  $H_2O_2$ , the treatment of cisplatin induced apoptosis in these four cancer cell lines (Figure 4B). For SC-M1, HSC-3, and PANC-1 cells, the occurrence of NAC cause the decreased on cisplatin-induced apoptosis (Figure 4B). We found that the percentage of apoptosis of cisplatin-treated Hep3B cells was not significantly affected by treatment with NAC, indicating that ROS might not play an essential role for cisplatin. Western blotting demonstrated that cisplatin increased the levels of LC3B-II in Hep3B cells (Figure S2A). In addition, the combination of cisplatin and CQ group showed the less anti-proliferative effect than cisplatin alone (Figure S2B). The above results

showed that cisplatin induces autophagy in Hep3B cells.

#### Nuclear PKM2 is important for $H_2O_2$ and cisplatin in gastric and oral cancer cells

Several reports have shown that PKM2 is a key molecule in regulating cancer metabolism, providing a correlation with tumorigenesis and poor prognosis [19, 31]. Modulation of PKM2





**Figure 4.** Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)- (A) and cisplatin-induced (B) apoptosis was reversed by pre-treatment with NAC. Flow cytometric analysis was performed on apoptotic cells pre-treated for 15 min with 5 mM NAC, incubated for 24 h with H<sub>2</sub>O<sub>2</sub> or cisplatin, and then stained with annexin V/PI. Points, means; bars, S.D. (n = 3). \*P < 0.05, \*\*P < 0.01.

has been successful in controlling cancer; thus, PKM2 could be a valuable antitumor biomarker [24, 32]. We tested the effects of H<sub>2</sub>O<sub>2</sub> and cisplatin on the phosphorylation of PKM2 in both gastric and oral cancer cells. Our data showed that both compounds decreased the levels of p-PKM2 in the nucleus (Figure 5A, 5B). To assess whether the ROS production is correlate with the nuclear translocation of PKM2. As shown in Figure 5A and 5B, the treatment of NAC partially reversed the levels of p-PKM2 in H<sub>2</sub>O<sub>2</sub>- and cisplatin-treated nuclear extracts, suggesting that PKM2 is involved in the ROS production by these two compounds.


Demaria et al. reported that nucleus PKM2 regulates *in vivo* growth by directly activating STAT3 [33]. Western blotting revealed that the levels of p-STAT3 were decreased in H<sub>2</sub>O<sub>2</sub>- and cisplatin-treated Hep3B cells (Figure S3A). Fluorescence analysis showed that the intensity of p-STAT3 was reduced following treatment with H<sub>2</sub>O<sub>2</sub> as well as cisplatin (Figure S3B).

## Discussion

It is well known that ROS are one of the by-products of oxygen consumption during the cellular metabolism and have been associated with cancer for centuries [10]. Numerous studies have shown that PKM2 is regard as an oncogene and the deletion of PKM2 leads to the growth advantage to tumor progression [18, 19]. In this study, H<sub>2</sub>O<sub>2</sub> and cisplatin were shown to mediate cytotoxicity through the production of ROS in gastric cancer, pancreatic cancer, oral cancer, and HCC cells. The inhibition of ROS generation prevented the cancer cells from apoptosis and PKM2 nuclear localization which induced by these two compounds.

Some evidences have revealed that excess ROS can trigger

genetic mutations such as KRAS and boosts tumor formation [6, 34]. However, in some research reports, ROS plays an opposite role in inhibiting cell growth and preventing the tumor invasion [12, 35]. Pilco-Ferreto et al. reported that doxorubicin inhibited the growth of breast cancer through decreasing NF-κB and increasing H<sub>2</sub>O<sub>2</sub> [36]. It has been reported that the free radical H<sub>2</sub>O<sub>2</sub> induce apoptosis through the activation of the death receptor Fas and p53 in HCC cells [37]. Itoh et al. also reported both H<sub>2</sub>O<sub>2</sub> and cisplatin cause the increased of intracellular ROS through increasing the activity of NADPH oxidase [38]. Our study showed that



**Figure 5.** Effects of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (A) and cisplatin (B) on p-PKM2 and PKM2. Two cancer cell lines (SC-M1 gastric cancer and HSC-3 oral cancer) were pre-treated with 5 mM NAC for 15 min and incubated for 24 h with H<sub>2</sub>O<sub>2</sub> or cisplatin. GAPDH or fibrillarin was used as a loading control. Cytosolic and nuclear extracts were isolated as described in the Materials and Methods section. Values are expressed as a percentage of the control.

both H<sub>2</sub>O<sub>2</sub> and cisplatin increased ROS generation in all these four cancer cell lines (gastric cancer, oral cancer, PANC-1, and HCC). Compared with the H<sub>2</sub>O<sub>2</sub> alone, the combination of the anti-oxidant NAC led to the inhibition of apoptosis in H<sub>2</sub>O<sub>2</sub>-treated tumor cell lines including SC-M1, HSC-3, and PANC-1 (**Figure 4**). The similar phenomenon was observed between cisplatin group and the combined group (NAC + cisplatin). Yazihan et al. reported that H<sub>2</sub>O<sub>2</sub> induces apoptosis after 48 h treatment through caspase-3 activation in the Hep3B cell line [39]. However, our results showed that H<sub>2</sub>O<sub>2</sub> did not induce apoptosis in Hep3B cells. Autophagy, one of cellular death, serves a tumor-suppressor function in hepatocellular carcinoma [40]. A previous study reported that H<sub>2</sub>O<sub>2</sub> causes hepatocyte injury and suppress liver cancer cell growth through activation of autophagy [41]. Instead of induc-

ing apoptosis, both H<sub>2</sub>O<sub>2</sub> and cisplatin induce autophagy in Hep3B cells.

Previous studies showed that PKM2 can dimerize prior to entering the nucleus, thereby regulating gene expression in the tumor cell energy supply pathway [20, 31]. Zhang et al. reported that the phosphorylation of PKM2 increases its nuclear localization, protecting the mitochondria from oxidative stress which leads to cell growth [42]. For example, the phosphorylation at Try105 of PKM2 has been demonstrated to promote the nuclear translocation and lead to the tumor growth [43]. Furthermore, p-PKM2 (Tyr105) is particularly observed in several human cancer cell lines such as Detroit-562 oral cancer, SK-Hep1 liver cancer, and PC3 prostate cancer [29, 43]. After exposure to H<sub>2</sub>O<sub>2</sub>, the intracellular concentration of ROS was increased and PKM2 activity was decreased in lung cancer cells [44]. In our study, H<sub>2</sub>O<sub>2</sub> and cisplatin were shown to reduce nuclear p-PKM2 levels

in SC-M1 gastric cancer and HSC-3 oral cancer cells, implying their apoptotic effect may be mediated through regulation of p-PKM2 (Tyr105). Notably, the decreased p-PKM2 levels induced by H<sub>2</sub>O<sub>2</sub> and cisplatin were reversed by pre-treatment with NAC, suggesting that PKM2 as a critical biomarker in ROS generation. Also, the data indicated that ROS decreased the p-PKM2 (Tyr105) as a downstream target of ROS in H<sub>2</sub>O<sub>2</sub>- and cisplatin-treated cells. PKM2 is an antitumor target that improves the prognosis of cancer. Zhou et al. reported that silencing PKM2 activates DNA damage proteins p-ATM and γH2AX and increases the susceptibility for the PARP inhibitor olaparib-treated ovarian cancer cells [45]. For image therapy, [<sup>18</sup>F]DASA-23, a new tracer for monitoring PKM2-inducing glycolytic glioblastoma has been used clinically [46]. Regulation of p-PKM2 has been shown to promote ERK

activation and Myc transcription, resulting in an enhanced Warburg effect [42]. Bi et al. reported that STAT3 promotes the Warburg effect by enhancing p-PKM2 in transformed hepatic progenitor cells *in vivo* [47]. A previous study demonstrated that PKM2 can be localized to the nucleus, where it directly activates STAT3 [33]. Consistent with this, our data showed decreased p-STAT3 protein expression in H<sub>2</sub>O<sub>2</sub>- and cisplatin-treated cells (Figure S3A). Furthermore, fluorescence analysis revealed that an interaction between p-PKM2 and STAT3 (Figure S3B), suggesting that nuclear PKM2 may regulate tumor growth through its interaction with STAT3. Taken together, these findings suggested that H<sub>2</sub>O<sub>2</sub>- and cisplatin inhibited cell growth, at least in part, by increasing ROS production and suppressing the PKM2/STAT3 signaling pathway.

## Conclusions

Our results showed that H<sub>2</sub>O<sub>2</sub> and cisplatin suppressed the growth of various cancer cell lines including SC-M1, HSC-3, PANC-1, and Hep3B. We demonstrated that the anti-tumor effects of these compounds were partially related to ROS generation and the inhibition of PKM2/STAT3 signaling. Therefore, the inhibition of nuclear PKM2 might be an important biomarker for cancer therapy.

## Acknowledgements

This work was supported by Ministry of Science and Technology (MOST 110-2320-B-110-003-MY3, 110-2314-B-039-034-MY3), National Science and Technology Council (NSTC 113-2320-B-110-007-MY3, NSTC 113-2320-B-110-005-MY3), Ministry of Health and Welfare (MOHW110-TDU-B-212-010001), National Health Research Institutes (NHRI-113A1-CA-CO-13242402, NHRI-114A1-CA-CO-13252502), and China Medical University Hospital (DMR-112-012, DMR-112-013, DMR-113-167).

## Disclosure of conflict of interest

None.

**Address correspondence to:** Dr. Jing-Ru Weng, Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan. Tel: +886-7-5252000; Ext. 5026; Fax: +886-7-5255020; E-mail: jrwen@mail.nsysu.edu.tw

## References


- [1] Siegel RL, Giaquinto AN and Jemal A. Cancer statistics, 2024. *CA Cancer J Clin* 2024; 74: 12-49.
- [2] Choudhary HB, Mandlik SK and Mandlik DS. Role of p53 suppression in the pathogenesis of hepatocellular carcinoma. *World J Gastrointest Pathophysiol* 2023; 14: 46-70.
- [3] Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J, Byeon SJ and Kang YK. Phase II study of induction chemotherapy with docetaxel, capecitabine, and cisplatin plus bevacizumab for initially unresectable gastric cancer with invasion of adjacent organs or paraaortic lymph node metastasis. *Cancer Res Treat* 2018; 50: 518-529.
- [4] Cao M, Shi E, Wang H, Mao L, Wu Q, Li X, Liang Y, Yang X, Wang Y and Li C. Personalized targeted therapeutic strategies against oral squamous cell carcinoma. An evidence-based review of literature. *Int J Nanomedicine* 2022; 17: 4293-4306.
- [5] Camhi SL, Lee P and Choi AM. The oxidative stress response. *New Horiz* 1995; 3: 170-182.
- [6] Nakamura H and Takada K. Reactive oxygen species in cancer: current findings and future directions. *Cancer Sci* 2021; 112: 3945-3952.
- [7] Ben-Eltriki M, Gayle EJ, Walker N and Deb S. Pharmacological significance of heme oxygenase 1 in prostate cancer. *Curr Issues Mol Biol* 2023; 45: 4301-4316.
- [8] Yan YD, Ji WX, Zhao N, Zhang JJ, Du J, Lu T and Gu WQ. Association between ACE1 and missed abortion: ACE1 promotes H2O2-induced trophoblast cell injury *in vitro*. *Biol Reprod* 2024; 111: 406-413.
- [9] Mbugua SN. Targeting tumor microenvironment by metal peroxide nanoparticles in cancer therapy. *Bioinorg Chem Appl* 2022; 2022: 5041399.
- [10] Rasouli M, Fattahi R, Nuoroozi G, Zarei-Behjani Z, Yaghoobi M, Hajmohammadi Z and Hosseinzadeh S. The role of oxygen tension in cell fate and regenerative medicine: implications of hypoxia/hyperoxia and free radicals. *Cell Tissue Bank* 2024; 25: 195-215.
- [11] Zhang Y, Hao M, Yang X, Zhang S, Han J, Wang Z and Chen HN. Reactive oxygen species in colorectal cancer adjuvant therapies. *Biochim Biophys Acta Mol Basis Dis* 2024; 1870: 166922.
- [12] Matsushita K, Okuda T, Mori S, Konno M, Eguchi H, Asai A, Koseki J, Iwagami Y, Yamada D, Akita H, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Kasahara Y, Morihiro K, Satoh T, Doki Y, Mori M, Ishii H and Obika S. A hydrogen peroxide activatable gemcitabine




- prodrug for the selective treatment of pancreatic ductal adenocarcinoma. *ChemMedChem* 2019; 14: 1384-1391.
- [13] Haciseyitoğlu AÖ, Doğan TÇ, Dilsiz SA, Canpinar H, Eken A and Bucurgat ÜÜ. Pitavastatin induces caspase-mediated apoptotic death through oxidative stress and DNA damage in combined with cisplatin in human cervical cancer cell line. *J Appl Toxicol* 2024; 44: 623-640.
  - [14] Morgan MJ and Liu ZG. Crosstalk of reactive oxygen species and NF-κB signaling. *Cell Res* 2011; 21: 103-115.
  - [15] Liou GY, Döppler H, DelGiorno KE, Zhang L, Leitges M, Crawford HC, Murphy MP and Storz P. Mutant KRas-induced mitochondrial oxidative stress in acinar cells upregulates EGFR signaling to drive formation of pancreatic precancerous lesions. *Cell Rep* 2016; 14: 2325-2336.
  - [16] Ren Y, Wang R, Weng S, Xu H, Zhang Y, Chen S, Liu S, Ba Y, Zhou Z, Luo P, Cheng Q, Dang Q, Liu Z and Han X. Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis. *Mol Cancer* 2023; 22: 130.
  - [17] Fogg VC, Lanning NJ and Mackeigan JP. Mitochondria in cancer: at the crossroads of life and death. *Chin J Cancer* 2011; 30: 526-539.
  - [18] Wang B and Pu R. Association between glycolysis markers and prognosis of liver cancer: a systematic review and meta-analysis. *World J Surg Oncol* 2023; 21: 390.
  - [19] Chen X, Chen S and Yu D. Protein kinase function of pyruvate kinase M2 and cancer. *Cancer Cell Int* 2020; 20: 523.
  - [20] Rihan M, Vineela Nalla L, Dharavath A, Patel S, Shard A and Khairnar A. Boronic acid derivative activates pyruvate kinase M2 indispensable for redox metabolism in oral cancer cells. *Bioorg Med Chem Lett* 2022; 59: 128539.
  - [21] Sun W, Ge Y, Cui J, Yu Y and Liu B. Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. *Mol Ther Oncolytics* 2021; 21: 87-97.
  - [22] Jaworska M, Szczudło J, Pietrzyk A, Shah J, Trojan SE, Ostrowska B and Kocemba-Pilarczyk KA. The Warburg effect: a score for many instruments in the concert of cancer and cancer niche cells. *Pharmacol Rep* 2023; 75: 876-890.
  - [23] Zahra K, Dey T, Ashish, Mishra SP and Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. *Front Oncol* 2020; 10: 159.
  - [24] Wang Y, Hao F, Nan Y, Qu L, Na W, Jia C and Chen X. PKM2 inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis. *Int J Biol Sci* 2018; 14: 1883-1891.
  - [25] Chen P, Lou L, Sharma B, Li M, Xie C, Yang F, Wu Y, Xiao Q and Gao L. Recent advances on PKM2 inhibitors and activators in cancer applications. *Curr Med Chem* 2024; 31: 2955-2973.
  - [26] Zamer BA, Cui ZG, Eladl MA, Hamad M and Muhammad JS. Estrogen treatment in combination with pyruvate kinase M2 inhibition precipitate significant cumulative antitumor effects in colorectal cancer. *J Biochem Mol Toxicol* 2024; 38: e23799.
  - [27] Wu J, Ding Z, Zhong M, Xi J, He Y, Zhang B and Fang J. Polyphyllin II induces apoptosis in fibrosarcoma cells via activating pyruvate kinase M2. *Chem Res Toxicol* 2024; 37: 1394-1403.
  - [28] Wang W, He Q, Sun J, Liu Z, Zhao L, Lu Z, Zhou X and Wang A. Pyruvate kinase M2 deregulation enhances the metastatic potential of tongue squamous cell carcinoma. *Oncotarget* 2017; 8: 68252-68262.
  - [29] Pak JN, Lee HJ, Sim DY, Park JE, Ahn CH, Park SY, Khil JH, Shim B, Kim B and Kim SH. Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells. *Phytother Res* 2023; 37: 4224-4235.
  - [30] Zhu H, Wu J, Zhang W, Luo H, Shen Z, Cheng H and Zhu X. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. *Sci Rep* 2016; 6: 30788.
  - [31] Kwon OH, Kang TW, Kim JH, Kim M, Noh SM, Song KS, Yoo HS, Kim WH, Xie Z, Pocalyko D, Kim SY and Kim YS. Pyruvate kinase M2 promotes the growth of gastric cancer cells via regulation of Bcl-xL expression at transcriptional level. *Biochem Biophys Res Commun* 2012; 423: 38-44.
  - [32] Weng JR, Gopula B, Chu PC, Hu JL and Feng CH. A PKM2 inhibitor induces apoptosis and autophagy through JAK2 in human oral squamous cell carcinoma cells. *Chem Biol Interact* 2023; 380: 110538.
  - [33] Demaria M and Poli V. PKM2, STAT3 and HIF-1α: the Warburg's vicious circle. *JAKSTAT* 2012; 1: 194-196.
  - [34] Messina S, De Simone G and Ascenzi P. Cysteine-based regulation of redox-sensitive Ras small GTPases. *Redox Biol* 2019; 26: 101282.
  - [35] Verma P, Rishi B, George NG, Kushwaha N, Dhandha H, Kaur M, Jain A, Jain A, Chaudhry S, Singh A, Siraj F and Misra A. Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment. *Pathol Oncol Res* 2023; 29: 1611412.

- [36] Pilco-Ferreto N and Calaf GM. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. *Int J Oncol* 2016; 49: 753-762.
- [37] Huang C, Li J, Zheng R and Cui K. Hydrogen peroxide-induced apoptosis in human hepatoma cells is mediated by CD95(APO-1/Fas) receptor/ligand system and may involve activation of wild-type p53. *Mol Biol Rep* 2000; 27: 1-11.
- [38] Itoh T, Terazawa R, Kojima K, Nakane K, Deguchi T, Ando M, Tsukamasa Y, Ito M and Nozawa Y. Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. *Free Radic Res* 2011; 45: 1033-1039.
- [39] Yazihan N, Ataoğlu H, Yener B and Aydin C. Erythropoietin attenuates hydrogen peroxide-induced damage of hepatocytes. *Turk J Gastroenterol* 2007; 18: 239-244.
- [40] Werling K. Role of autophagy in the pathogenesis of liver diseases. *Orv Hetil* 2011; 152: 1955-1961.
- [41] Fang M and Zhong C. Vitamin D receptor regulates autophagy to inhibit apoptosis and promote proliferation in hepatocyte injury. *J Nippon Med Sch* 2023; 90: 89-95.
- [42] Zhang Z, Deng X, Liu Y, Liu Y, Sun L and Chen F. PKM2, function and expression and regulation. *Cell Biosci* 2019; 9: 52.
- [43] Tai WT, Hung MH, Chu PY, Chen YL, Chen LJ, Tsai MH, Chen MH, Shiau CW, Boo YP and Chen KF. SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma. *Oncotarget* 2016; 7: 22193-22205.
- [44] Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG and Cantley LC. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. *Science* 2011; 334: 1278-1283.
- [45] Zhou S, Li D, Xiao D, Wu T, Hu X, Zhang Y, Deng J, Long J, Xu S, Wu J, Li G, Peng M and Yang X. Inhibition of PKM2 enhances sensitivity of olaparib to ovarian cancer cells and induces DNA damage. *Int J Biol Sci* 2022; 18: 1555-1568.
- [46] Beinat C, Patel CB, Haywood T, Murty S, Naya L, Castillo JB, Reyes ST, Phillips M, Buccino P, Shen B, Park JH, Koran MEI, Alam IS, James ML, Holley D, Halbert K, Gandhi H, He JQ, Granucci M, Johnson E, Liu DD, Uchida N, Sinha R, Chu P, Born DE, Warnock GI, Weissman I, Hayden-Gephart M, Khalighi M, Massoud TF, Iagaru A, Davidzon G, Thomas R, Nagpal S, Recht LD and Gambhir SS. A clinical PET imaging tracer ([<sup>18</sup>F]DASA-23) to monitor pyruvate kinase M2-induced glycolytic reprogramming in glioblastoma. *Clin Cancer Res* 2021; 27: 6467-6478.
- [47] Bi YH, Han WQ, Li RF, Wang YJ, Du ZS, Wang XJ and Jiang Y. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. *World J Gastroenterol* 2019; 25: 1936-1949.


## H<sub>2</sub>O<sub>2</sub> and cisplatin induce apoptosis



**Figure S1.** Effects of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) on autophagy. A. Hep3B cells were treated with H<sub>2</sub>O<sub>2</sub> for 24 h and western blot was performed. B. Cells were treated with H<sub>2</sub>O<sub>2</sub> or in combination with chloroquine (CQ), and cell viability was determined using MTT assays. Points, mean; bars, S.D. (n = 3) \**P* < 0.05.



**Figure S2.** Effects of cisplatin on autophagy. A. Hep3B cells were treated with cisplatin for 24 h and western blot was performed. B. Cells were treated with cisplatin or in combination with chloroquine (CQ), and cell viability was determined using MTT assays. Points, mean; bars, S.D. (n = 3) \*\**P* < 0.01.



**Figure S3.** Expression/phosphorylation of STAT3 in hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)- and cisplatin-treated Hep3B cells. A. Western blotting of p-STAT3 and STAT3 protein levels after treatment of H<sub>2</sub>O<sub>2</sub> or cisplatin for 24 h. B. Fluorescence analysis of STAT3 in Hep3B cells in response to H<sub>2</sub>O<sub>2</sub> or cisplatin.